RATIONALE: Differential effects of δ(B) and δ(C) subtypes of Ca²⁺/calmodulin-dependent protein kinase (CaMKII) on cardiomyocyte Ca²⁺ handling and survival have been suggested to result from their respective nuclear versus cytosolic localizations. CaMKIIδ subtype localization and its relationship to enzyme activation and target phosphorylation have not, however, been systematically evaluated. OBJECTIVE: To determine whether CaMKIIδ subtypes are restricted to a particular subcellular location and assess the relationship of localization to enzyme activation and function. METHODS AND RESULTS: CaMKIIδ is highly expressed in mouse heart and cardiomyocytes and concentrated in sarcoplasmic reticulum (SR)/membrane and nuclear fractions. CaMKIIδ(B) and δ(C) subtypes differ by a nuclear localization sequence, but both are present in nuclear and SR/membrane fractions. Nonselective subtype distribution is also seen in mice overexpressing CaMKIIδ(B) or δ(C), even in a CaMKIIδ null background. Fluorescently tagged CaMKIIδ(B) expressed in cardiomyocytes concentrates in nuclei whereas δ(C) concentrates in cytosol, but neither localization is exclusive. Mouse hearts exposed to phenylephrine show selective CaMKIIδ activation in the nuclear (versus SR) compartment, whereas caffeine selectively activates CaMKIIδ in SR (versus nuclei), independent of subtype. Compartmentalized activation extends to functional differences in target phosphorylation at CaMKII sites: phenylephrine increases histone deacetylase 5 phosphorylation (Ser498) but not phospholamban (Thr17), whereas the converse holds for caffeine. CONCLUSIONS: These studies demonstrate that CaMKIIδ(B) and δ(C) are not exclusively restricted to the nucleus and cytosol and that spatial and functional specificity in CaMKIIδ activation is elicited by mobilization of different Ca²⁺ stores rather than by compartmentalized subtype localization.
RATIONALE: Differential effects of δ(B) and δ(C) subtypes of Ca²⁺/calmodulin-dependent protein kinase (CaMKII) on cardiomyocyte Ca²⁺ handling and survival have been suggested to result from their respective nuclear versus cytosolic localizations. CaMKIIδ subtype localization and its relationship to enzyme activation and target phosphorylation have not, however, been systematically evaluated. OBJECTIVE: To determine whether CaMKIIδ subtypes are restricted to a particular subcellular location and assess the relationship of localization to enzyme activation and function. METHODS AND RESULTS:CaMKIIδ is highly expressed in mouse heart and cardiomyocytes and concentrated in sarcoplasmic reticulum (SR)/membrane and nuclear fractions. CaMKIIδ(B) and δ(C) subtypes differ by a nuclear localization sequence, but both are present in nuclear and SR/membrane fractions. Nonselective subtype distribution is also seen in mice overexpressing CaMKIIδ(B) or δ(C), even in a CaMKIIδ null background. Fluorescently tagged CaMKIIδ(B) expressed in cardiomyocytes concentrates in nuclei whereas δ(C) concentrates in cytosol, but neither localization is exclusive. Mouse hearts exposed to phenylephrine show selective CaMKIIδ activation in the nuclear (versus SR) compartment, whereas caffeine selectively activates CaMKIIδ in SR (versus nuclei), independent of subtype. Compartmentalized activation extends to functional differences in target phosphorylation at CaMKII sites: phenylephrine increases histone deacetylase 5 phosphorylation (Ser498) but not phospholamban (Thr17), whereas the converse holds for caffeine. CONCLUSIONS: These studies demonstrate that CaMKIIδ(B) and δ(C) are not exclusively restricted to the nucleus and cytosol and that spatial and functional specificity in CaMKIIδ activation is elicited by mobilization of different Ca²⁺ stores rather than by compartmentalized subtype localization.
Authors: Tong Zhang; Lars S Maier; Nancy D Dalton; Shigeki Miyamoto; John Ross; Donald M Bers; Joan Heller Brown Journal: Circ Res Date: 2003-04-03 Impact factor: 17.367
Authors: Shigeki Miyamoto; Nicole H Purcell; Jeffrey M Smith; Tianyan Gao; Ross Whittaker; Katherine Huang; Rene Castillo; Chris C Glembotski; Mark A Sussman; Alexandra C Newton; Joan Heller Brown Journal: Circ Res Date: 2010-06-24 Impact factor: 17.367
Authors: H E Shubeita; P M McDonough; A N Harris; K U Knowlton; C C Glembotski; J H Brown; K R Chien Journal: J Biol Chem Date: 1990-11-25 Impact factor: 5.157
Authors: H Ito; Y Hirata; S Adachi; M Tanaka; M Tsujino; A Koike; A Nogami; F Murumo; M Hiroe Journal: J Clin Invest Date: 1993-07 Impact factor: 14.808
Authors: Ali Reza Saadatmand; Viviana Sramek; Silvio Weber; Daniel Finke; Matthias Dewenter; Carsten Sticht; Norbert Gretz; Till Wüstemann; Marco Hagenmueller; Stephan R Kuenzel; Stefanie Meyer-Roxlau; Martin Kramer; Samuel Sossalla; Lorenz H Lehmann; Susanne Kämmerer; Johannes Backs; Ali El-Armouche Journal: Proc Natl Acad Sci U S A Date: 2019-10-16 Impact factor: 11.205
Authors: Sara C Sebag; Olha M Koval; John D Paschke; Christopher J Winters; Omar A Jaffer; Ryszard Dworski; Fayyaz S Sutterwala; Mark E Anderson; Isabella M Grumbach Journal: JCI Insight Date: 2017-02-09
Authors: Charles B B Gray; Takeshi Suetomi; Sunny Xiang; Shikha Mishra; Erik A Blackwood; Christopher C Glembotski; Shigeki Miyamoto; B Daan Westenbrink; Joan Heller Brown Journal: J Mol Cell Cardiol Date: 2017-01-07 Impact factor: 5.000
Authors: Sarah J Lehman; Lauren Tal-Grinspan; Melissa L Lynn; Joshua Strom; Grace E Benitez; Mark E Anderson; Jil C Tardiff Journal: Circulation Date: 2019-03-19 Impact factor: 29.690